{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:26:57Z","timestamp":1794317217571,"version":"4.9.0"},"reference-count":9,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:p>An insurance company denied coverage for an inflammatory bowel disease medication, stating that the lack of a pediatric Food and Drug Administration indication made that treatment experimental. This was legally permissible. The patient\u2019s pediatric gastroenterologist partnered with others to create a new state law that mandated insurance coverage for medications in children when the treatment was covered for adult patients and there were data to support pediatric efficacy and safety. Coalition building included support from a hospital system, community petitions, and interactions with legislators. Family and physician testimony supported passage of the law, in effect since 2023. The patient was able to obtain the necessary treatment, and the law has been used to help other children gain access to prescribed treatments. This process can serve as a model for similar advocacy in other states.<\/jats:p>","DOI":"10.1542\/peds.2026-076816","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:02:33Z","timestamp":1792454553000},"source":"Crossref","is-referenced-by-count":0,"title":["Driving Legislative Change for Access to Medications"],"prefix":"10.1542","volume":"158","author":[{"given":"Ala","family":"Aldabbas","sequence":"first","affiliation":[{"name":"1Ochsner Health System, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Giefer","sequence":"additional","affiliation":[{"name":"1Ochsner Health System, New Orleans, Louisiana"},{"name":"2Xavier Ochsner College of Medicine, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Carlson","sequence":"additional","affiliation":[{"name":"1Ochsner Health System, New Orleans, Louisiana"},{"name":"2Xavier Ochsner College of Medicine, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"issue":"1","key":"2026111007571563700_r1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(22)00307-7","article-title":"Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study","volume":"8","author":"Atia","year":"2023","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"3","key":"2026111007571563700_r2","doi-asserted-by":"crossref","first-page":"e2022058882","DOI":"10.1542\/peds.2022-058882","article-title":"Considerations in the Determination of Medical Necessity in Children: Application to Contractual Language","volume":"150","author":"Giardino","year":"2022","journal-title":"Pediatrics."},{"issue":"1","key":"2026111007571563700_r3","first-page":"4","article-title":"Use of approved drugs for unlabeled indications","volume":"12","author":"Food and Drug Administration","year":"1982","journal-title":"FDA Drug Bull."},{"issue":"1","key":"2026111007571563700_r4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamapediatrics.2018.3416","article-title":"Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act","volume":"173","author":"Hwang","year":"2019","journal-title":"JAMA Pediatr."},{"key":"2026111007571563700_r5"},{"issue":"3","key":"2026111007571563700_r6","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3758\/s13423-020-01853-1","article-title":"Memory and comprehension of narrative versus expository texts: A meta-analysis","volume":"28","author":"Mar","year":"2021","journal-title":"Psychon Bull Rev."},{"key":"2026111007571563700_r7"},{"issue":"3","key":"2026111007571563700_r8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1542\/pir.2024-006452","article-title":"Monoclonal Antibody Therapies for Children","volume":"46","author":"Daggumati","year":"2025","journal-title":"Pediatr Rev."},{"key":"2026111007571563700_r9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/1741-7015-11-238","article-title":"Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital","volume":"11","author":"Bellis","year":"2013","journal-title":"BMC Med."}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2026-076816\/1978868\/pediatrics.2026076816.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2026-076816\/1978868\/pediatrics.2026076816.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:57:24Z","timestamp":1794315444000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/158\/5\/e2026076816\/210993\/Driving-Legislative-Change-for-Access-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":9,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10,20]]},"published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2026-076816","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"article-number":"e2026076816"}}